Several studies have demonstrated that when designed to recognize tumour-associated antigens, IgE antibodies can activate immune cells, such as monocytes [8,15] and macrophages [21,22], to engender anti-tumour immunity by effector functions. This evidence concerns the gene IGHE and neoplasm.